Trevi Therapeutics (TRVI) Operating Income (2018 - 2022)

Trevi Therapeutics' Operating Income history runs 8 years deep, the most recent figure standing at -$10.2 million for Q4 2025.

• In Q4 2025, Operating Income rose 16.52% year-over-year to -$10.2 million; the TTM figure through Dec 2025 stood at -$50.1 million (up 2.76% YoY), while the FY2025 annual figure was -$49.3 million, up 4.26% from the prior year.
• Operating Income for Q4 2025 stood at -$10.2 million, up from -$13.9 million in the prior quarter.
• The five-year high for Operating Income was -$6.7 million in Q4 2022, with the low at -$14.1 million in Q3 2024.
• The 5-year median for Operating Income is -$8.9 million (2023), against an average of -$9.8 million.
• The sharpest annual moves came in 2022 and 2024: Operating Income climbed 19.53% in 2022, then tumbled 58.54% in 2024.
• Trevi Therapeutics' Operating Income stood at -$8.3 million in 2021, then increased by 19.53% to -$6.7 million in 2022, then plunged by 34.19% to -$8.9 million in 2023, then plunged by 37.05% to -$12.2 million in 2024, then rose by 16.52% to -$10.2 million in 2025.
• Business Quant data shows TRVI's Operating Income at -$10.2 million in Q4 2025, -$13.9 million in Q3 2025, and -$13.7 million in Q2 2025.